drugset / Trial / NCT00915135

Efficacy and Safety of Ramelteon on Chronic Insomnia

NCT00915135

Phase 2 Completed 66 enrolled Takeda
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine the dose response of Ramelteon, once daily (QD), in Japanese subjects with Chronic Insomnia

Timeline

Start
2002-05
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 4 mg Oral
Subject Ramelteon Unknown 8 mg Oral
Subject Ramelteon Unknown 16 mg Oral
Subject Ramelteon Unknown 32 mg Oral

Indications